Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference58 articles.
1. Horn L, Reck M, Spigel DR. The future of immunotherapy in the treatment of small cell lung cancer. Oncologist. 2016;21:910–21.
2. Horn L, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1809064 The IMpower133 trial was one of two large phase 3 trials that showed an overall survival benefit with adding immunotherapy to first-line platinum-based chemotherapy. This trial led to the FDA approval of atezolizumab, changing the frontline treatment paradigm for patients with ED SCLC for the first time in decades.
3. ••Paz-Ares L, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019. In addition to the IMpower133 trial, the CASPIAN study was another phase III trial that showed a benefit when adding immunotherapy to first-line treatment in ED SCLC. These results led the FDA to grant orphan drug designation to durvalumab in the treatment of SCLC.
4. Chung HC, Lopez-Martin JA, Kao SCH, Miller WH, Ros W, Gao B, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. J Clin Oncol. 2018;36:–8506.
5. Ready N, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2019;14:237–44.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献